Dr. Harold E. Selick is the Chairman of the company. Prior to this, he served as the Chief Executive Officer of Threshold Pharmaceuticals, which recently merged with Molecular Templates. Dr. Selick also held the position of Chief Executive Officer at Camitro Corporation and served as Vice President of Research at Affymax Research Institute. Currently, he is also the Vice Chancellor for Business Development, Innovation, and Partnerships at the University of California, San Francisco, and serves as the Chairman of Molecular Templates.

Mr. Dinesh V. Patel has been the Chief Executive Officer, President and Director of the company since 2008. Prior to this, he served as the President and Chief Executive Officer of Arete Therapeutics and Miikana Therapeutics. Mr. Patel also served as the Senior Vice President of Drug Discovery and Licensing at Vicuron and Director of Chemistry at Affymax. Previously, he also served as the Medicinal Chemist at Bristol Myers Squibb.

Mr. Asif Ali has been an Executive Vice President and the Chief Financial Officer of the company since 2022. Prior to this, he served as the Chief Accounting Officer and Vice President in the Finance division at Theravance Biopharma from 2018 to 2022, and as Vice President and Controller at Depomed Inc from 2012 to 2018. Mr. Ali also held the position of Director of Finance and Accounting for Nevada Property from 2010 to 2011, and worked in public accounting in the life sciences practice of PricewaterhouseCoopers from 2004 to 2009.

Dr. Arturo Molina has been the Chief Medical Officer of the company since 2022. Prior to this, he served as the Chief Medical Officer at Sutro Biopharma from 2017 to 2022 and was the Vice President of Oncology Scientific Innovation at Johnson & Johnson. He also held the position of Chief Medical Officer at Cougar Biotechnology. Previously, Mr. Molina served as a Staff Physician in the Department of Hematology/Bone Marrow Transplantation and the Department of Medical Oncology/Therapeutics Research at the City of Hope Comprehensive Cancer Center from 1991 to 2002.

Mr. Mohammad Masjedizadeh has been the Chief Technical Officer and Executive Vice President of the company since 2021. Prior to this, Mr. Masjedizadeh served as the Executive Vice President of Pharmaceutical Development at the company from 2017 to 2021. Before that, he held the position of Vice President and Senior Director of Technical Operations at Principia Biopharma from 2012 to 2017. Previously, he spent over two decades at Roche Pharmaceuticals, where he served as the Director of Drug Substance & Supply from 1991 to 2012.